EMERGENT BIOSOLUTIONS INC (EBS) Stock Analyst Ratings
USA - NYSE:EBS - US29089Q1058 - Common Stock
9.74 USD
+0.08 (+0.83%)
9.7348 USD
-0.01 (-0.05%)
ChartMill assigns a Buy % Consensus number of 74% to EBS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 13.77. This target is 41.38% above the current price.
EBS was analyzed by 7 analysts. The buy percentage consensus is at 74. So analysts seem to be have mildly positive about EBS.
In the previous month the buy percentage consensus was at a similar level.
EBS was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-09-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-30 | HC Wainwright & Co. | Initiate | Buy |
| 2024-11-07 | Benchmark | Maintains | Buy -> Buy |
| 2024-09-13 | Rodman & Renshaw | Reiterate | Buy -> Buy |
| 2024-08-22 | Rodman & Renshaw | Initiate | Buy |
| 2024-08-16 | Benchmark | Reiterate | Buy -> Buy |
| 2024-08-09 | Benchmark | Reiterate | Buy -> Buy |
| 2024-07-03 | Benchmark | Reiterate | Buy -> Buy |
| 2024-07-02 | Benchmark | Reiterate | Buy -> Buy |
| 2024-06-24 | Benchmark | Reiterate | Buy -> Buy |
| 2024-06-21 | Benchmark | Reiterate | Buy -> Buy |
| 2024-06-20 | Benchmark | Maintains | Buy -> Buy |
| 2024-04-11 | Benchmark | Reiterate | Buy -> Buy |
| 2024-03-07 | Benchmark | Upgrade | Hold -> Buy |
| 2023-11-20 | JP Morgan | Reiterate | Underweight |
| 2023-08-29 | Benchmark | Downgrade | Buy -> Hold |
| 2023-05-31 | Benchmark | Reiterate | Buy -> Buy |
| 2023-05-19 | Benchmark | Reiterate | Buy -> Buy |
| 2023-04-10 | Benchmark | Upgrade | Hold -> Buy |
| 2023-03-17 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2022-11-10 | Benchmark | Downgrade | Buy -> Hold |
| 2022-11-09 | Chardan Capital | Maintains | Buy |
| 2022-09-12 | Cowen & Co. | Maintains | Market Perform |
| 2022-05-04 | Wells Fargo | Maintains | Equal-Weight |
| 2022-04-29 | Chardan Capital | Maintains | Buy |
EMERGENT BIOSOLUTIONS INC / EBS FAQ
What do analysts expect the price target to be for EMERGENT BIOSOLUTIONS INC (EBS)?
7 analysts have analysed EBS and the average price target is 13.77 USD. This implies a price increase of 41.38% is expected in the next year compared to the current price of 9.74.
What is the consensus rating for EBS stock?
The consensus rating for EMERGENT BIOSOLUTIONS INC (EBS) is 74.2857 / 100 . This indicates that analysts generally have a positive outlook on the stock.